TNBC Off-Label Drugs in Treatment Resistance Research
Research notes on repurposed off-label drugs being explored to counter treatment resistance in triple-negative breast cancer, including pitavastatin, melatonin, and metformin
Repurposed drugs matter in TNBC resistance research because they can move faster than brand-new compounds.
They already have human safety history, established manufacturing, and real-world prescribing experience.
That does not make them proven cancer treatments.
It does make them worth tracking when the resistance biology is strong.
In this section
This page is educational only.
The evidence here is mainly preclinical.
Do not start or switch to an off-label drug on the basis of this page without oncology and pharmacy review.
Why repurposed drugs matter here
Treatment-resistant TNBC often depends on several escape routes at once.
These can include apoptosis evasion, cancer stem-cell persistence, drug efflux, and bypass survival signalling.
Repurposed drugs are interesting when they hit more than one of those routes together.
Pitavastatin as a novel Mcl-1 inhibitor
A notable 2025 paper from Korea University placed pitavastatin on the TNBC resistance map.
The study reported that pitavastatin directly binds and inhibits Mcl-1, an anti-apoptotic protein that is often upregulated in paclitaxel-resistant TNBC.
That matters because Mcl-1 helps resistant tumour cells avoid programmed cell death.
By inhibiting Mcl-1, pitavastatin was reported to:
increase mitochondrial ROS
reduce mitochondrial membrane potential
deplete ATP
trigger caspase-mediated apoptosis in resistant cells
The same study also linked pitavastatin to broader anti-resistance effects.
Reported findings included:
suppression of cancer stem-cell features, including high ALDH1 activity and CD44high/CD24low phenotype
downregulation of P-glycoprotein, a major drug-efflux driver
disruption of AKT/STAT3 survival signalling
The combination data was the most striking part.
When combined with paclitaxel, pitavastatin showed synergistic activity in patient-derived tumour organoids and significantly reduced tumour growth and lung metastasis in animal models, without overt toxicity in those models.
"We report for the first time that pitavastatin is a direct inhibitor of Mcl-1 and targets heterogeneity in TNBC cells via the suppression of CSC-like properties, thereby preventing distant metastasis and counteracting paclitaxel resistance."
— Prof. Seo, Korea University
This makes pitavastatin one of the more credible repurposing leads in paclitaxel-resistant TNBC.
It is still not a validated TNBC treatment in people.
Q&A: Do other statins do the same thing?
Great question.
The short answer is no, not in the same way.
Pitavastatin is the standout statin for this specific mechanism.
It is the only statin currently reported to directly bind Mcl-1 in TNBC.
It also has a roughly 12-hour half-life, which may help sustain the apoptotic signalling needed to reduce Mcl-1 and increase pro-apoptotic proteins such as PUMA and NOXA.
Other statins have overlapping but not identical activity.
Statins with related apoptosis or Mcl-1 relevance
Simvastatin — reduces Mcl-1 expression indirectly and activates integrated stress response signalling in some cancer models
Lovastatin — also shows indirect Mcl-1 and integrated stress response effects in haematologic models
Atorvastatin — has mitochondrial apoptosis relevance in lymphoma models, but is less studied for direct Mcl-1 biology
Fluvastatin — has apoptosis-inducing activity in some combination settings, including kidney-cancer work
What all statins share
All statins inhibit HMG-CoA reductase.
That blocks the mevalonate pathway, which cancer cells use for survival signalling, membrane biology, and prenylation of proteins such as Ras and Rho.
That shared upstream action may help explain why several statins can sensitise cancer cells to apoptosis.
Pitavastatin appears to go further by adding direct Mcl-1 binding on top of that.
Practical takeaway
Being on a common statin such as atorvastatin, rosuvastatin, or simvastatin is not the same as the pitavastatin result reported here.
They should not be treated as interchangeable for this mechanism.
Melatonin
The short version: Melatonin is a naturally produced hormone and a low-cost supplement with a growing TNBC resistance literature.
It now has a newly identified 2026 target in the FAK–PD-L1 axis.
How it works in TNBC resistance
A January 2026 paper in Frontiers in Oncology reported that melatonin suppresses FAK signalling and lowers PD-L1 expression in TNBC cells.
That matters because PD-L1 helps resistant tumours hide from immune attack.
Reducing it may help unmask the tumour and improve immune surveillance.
This makes melatonin especially relevant to immunotherapy-combination thinking.
The same study also reported reversal of EMT markers in MDA-MB-231 and MDA-MB-468 cells.
Melatonin increased E-cadherin and reduced β-catenin plus vimentin.
That pattern fits lower invasiveness and less metastatic potential.
A February 2026 study in Cancer Letters added a second resistance angle.
It reported that melatonin suppresses glycolysis and disrupts DNA repair in TNBC.
That matters because resistant TNBC often depends on metabolic rewiring and better damage repair to survive chemotherapy stress.
Earlier work also showed that melatonin can re-sensitise olaparib-resistant TNBC cells.
Reported effects included less cancer stem-cell renewal and less invasiveness.
Why melatonin stands out
Melatonin is notable because it appears to hit several resistance routes at once:
EMT reversal
immune evasion through PD-L1 reduction
glycolytic pressure on Warburg-like metabolism
cancer stem-cell suppression
It is also inexpensive and already widely used.
The limit is the same as with many repurposing leads.
Most of the strongest evidence is still preclinical.
Human TNBC trial data remains limited.
Metformin
The short version: Metformin is one of the best-studied repurposed drugs in oncology.
In TNBC, the evidence now includes both mechanistic work and real-world survival signals.
Survival signal and updated mechanisms
An October 2025 report summarising early-stage TNBC data found that metformin and statins were each associated with better survival when patients were already taking them for metabolic or cardiovascular reasons.
That does not prove causation.
It does add real-world weight to the repurposing rationale.
It also raises the possibility that metformin and statins could be synergistic, which matters in the context of the pitavastatin findings above.
A 2025 review of metformin-based combination approaches in TNBC helps clarify why the drug keeps resurfacing.
The main mechanisms discussed were:
AMPK activation with downstream mTOR suppression
reduction of the CD44high/CD24low cancer stem-cell compartment
immune-microenvironment shifts that may improve checkpoint-inhibitor response
Newer 2025 work adds more specificity.
One study reported that metformin can target FGFR4, a receptor often overexpressed in TNBC, and enhance the effect of HDAC inhibitors.
Another line of work combined metformin with hemin in BACH1-depleted TNBC cells.
That combination forced a metabolic shift and then suppressed mitochondrial respiration, with tumour-suppression effects in mouse models.
Where metformin sits right now
Metformin is still not standard of care in TNBC.
Clinical trials are ongoing.
The main reason it remains interesting is that it is relatively low risk, cheap, and mechanistically broad.
It looks most plausible as an adjunctive sensitisation strategy rather than as a stand-alone anti-cancer treatment.
That is especially relevant when metabolic dysfunction is already part of the wider clinical picture.
Aspirin
Aspirin deserves its own place in TNBC off-label research because the signal is less about bulk tumour shrinkage and more about metastatic spread, platelet biology, and immune evasion.
That makes it especially relevant in triple-negative disease, where TXA2 and platelet-supported metastasis may matter more.
The most useful TNBC-linked reading here is the dedicated Aspirin in breast cancer page.
That page covers:
the mixed human evidence in breast cancer
the TXA2 and platelet-metastasis logic that looks especially relevant to TNBC
why aspirin is still investigational, despite credible anti-metastatic biology
For the mechanism-first deep dive, see Aspirin and Thromboxane A2 (TXA2).
Where to dig next
Several other off-label leads look worth tracking as this page grows.
Most of these signals come from a broader review covering multiple repurposed-drug candidates in TNBC, plus a small number of newer single-topic papers.
Ivermectin and mebendazole
Both have preclinical TNBC data tied to proliferation control and cancer stem-cell suppression in the repurposed-drug review.
Ivermectin is often discussed through WNT–TCF signalling.
Mebendazole is better known for microtubule disruption and broader anti-resistance overlap.
For the fuller mebendazole track, see Mebendazole in Oncology.
Itraconazole and NSAID strategies
Itraconazole remains relevant because of Hedgehog, VEGF, and anti-metastatic biology in both the repurposed-drug review and the TNBC-specific itraconazole breast-cancer page.
Aspirin, indomethacin, and wider COX-2 inhibition also deserve attention because COX-2 overexpression can support immune evasion and metastasis in TNBC, again summarised in the same review.
Some preclinical work suggests these agents can increase sensitivity to paclitaxel or doxorubicin.
Antidepressants, HORMAD1, and melatonin combinations
Fluoxetine and imipramine are being explored for their effects on multidrug-resistance pumps plus autophagy and apoptosis in the repurposed-drug review.
HORMAD1 is a newer 2026 target worth watching as the literature matures, based on the March 2026 research summary.
The melatonin + immunotherapy angle also looks like a natural next deep dive because the FAK–PD-L1 melatonin paper fits directly with pembrolizumab-era TNBC logic.
What this means in practice
Pitavastatin, melatonin, and metformin each show a different version of the same pattern.
They touch more than one resistance route at once.
That is exactly why they keep appearing in TNBC literature.
The honest picture is still mixed.
Pitavastatin has one of the clearest mechanism-first stories.
Melatonin looks unusually broad for a low-cost adjunct, especially at the immune-evasion and EMT level.
Metformin has the widest general oncology literature and now some real-world TNBC survival context.
None of them are validated TNBC treatments on the basis of the current evidence.
They are best understood as research leads and possible future combination partners.
For the broader on-the-horizon side of TNBC resistance research, see Emerging Resistance Strategies.
References
Melatonin suppresses glycolysis and disrupts DNA repair in TNBC
Melatonin restores olaparib sensitivity in resistant TNBC models
Statins and Metformin Improve Survival in Patients with Triple-Negative Breast Cancer
Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
Metformin boosts triple-negative breast cancer treatment efficacy through FGFR4-related findings
Novel repurposed drug combo shows potential in triple-negative breast cancer
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.